Treatment of childhood kaposiform hemangioendothelioma with sirolimus

134Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Sirolimus (Rapamune), a mammalian target of Rapamycin (mTOR) inhibitor, which has been used extensively in children following solid organ transplantation, has been demonstrated to have anti-angiogenic activity in pre-clinical models. Limited experience suggests that it may have application to the treatment of vascular lesions. We describe our experience with a 1-year-old female with a kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon who had rapid and dramatic response to sirolimus (0.1mg/kg/day). This case provides further rationale for clinical trials of sirolimus in the treatment of vascular lesions. © 2010 Wiley-Liss, Inc.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Blatt, J., Stavas, J., Moats-Staats, B., Woosley, J., & Morrell, D. S. (2010). Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatric Blood and Cancer, 55(7), 1396–1398. https://doi.org/10.1002/pbc.22766

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

30%

Lecturer / Post doc 5

25%

Researcher 5

25%

Professor / Associate Prof. 4

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 22

88%

Agricultural and Biological Sciences 1

4%

Biochemistry, Genetics and Molecular Bi... 1

4%

Chemistry 1

4%

Save time finding and organizing research with Mendeley

Sign up for free